Zodasiran - Arrowhead Pharmaceuticals
Alternative Names: ARO-ANG3; ARO-ANG33; VSA-003Latest Information Update: 09 Dec 2024
At a glance
- Originator Roche
- Developer Arrowhead Pharmaceuticals
- Class Antihyperlipidaemics; Cardiovascular therapies; Small interfering RNA
- Mechanism of Action ANGPTL3 protein expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Dyslipidaemias; Hyperlipoproteinaemia type II
Most Recent Events
- 02 Dec 2024 Visirna Therapeutics plans a phase III trial for Hypercholesterolemia (In adolescents, In adults, In the elderly) in China (SC, Injection) (NCT06712771)
- 24 Sep 2024 Arrowhead Pharmaceuticals completes a phase II trial in Dyslipidaemias in New Zealand, Canada, Australia and USA (SC) (NCT04832971)
- 30 May 2024 Updated efficacy and adverse event data from a phase IIb ARCHES-2 in Dyslipidaemias released by Arrowhead pharmaceuticals